ArticleFrontiers in veterinary science2026
An investigation of per- and polyfluoroalkyl concentrations in dogs and cats with endocrine disorders.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Per- and polyfluoroalkyl substances (PFAS) are persistent environmental contaminants with endocrine-disrupting and potential carcinogenic effects in humans. Data on PFAS exposure in companion animals are limited. This study quantified PFAS concentrations in dog and cat serum and investigated associations with endocrine disorders. Methods: This retrospective study included 179 dogs from the Universities of Bologna and Utrecht, and 84 cats from the University of Bologna, sampled between 2021 and 2025. The population comprised 23 healthy dogs, 35 healthy cats, and animals with endocrine disorders, including 49 cats with hyperthyroidism, 64 dogs with pituitary-dependent hypercortisolism, 16 with primary hyperparathyroidism, and 85 with adrenal tumors. Eleven PFAS were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Between-group differences were evaluated using nonparametric tests, associations with disease status using age-adjusted generalized linear models, and correlations with age and body condition score using Spearman's rank correlation. Results: Eight PFAS were detected in dogs and nine in cats. The most frequently detected compounds were perfluorooctanesulfonic acid (PFOS, 99.5%), perfluorohexanesulfonic acid (PFHxS, 69.0%), and perfluorooctanoic acid (PFOA, 68.5%) in dogs, and PFOS (99.0%) and PFOA (96.0%) in cats. Dogs from Utrecht had higher PFOS concentrations than dogs from Bologna. Unadjusted between-group differences varied by species, with higher PFAS concentrations in healthy cats but higher concentrations of some PFAS in certain canine diseased groups. After adjustment for age, no PFAS was independently associated with disease status in either species. A weak negative correlation between ∑PFAS and age was observed in dogs ( Discussion and conclusions: PFAS exposure was widespread in both species, with higher PFOS concentrations in dogs from the Dutch cohort. The inverse association between PFAS concentrations and age, together with the older age of diseased animals, suggests that age substantially contributed to the observed between-group differences. Further longitudinal studies, including minimally exposed control populations, are warranted to clarify the health implications of PFAS exposure in companion animals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.